Pacira BioSciences (PCRX) saw a slight increase of 0.4% in its stock price after DOMA Perpetual Capital Management, holding a 6.8% stake, urged the company to consider a sale. The investor criticized the current management for poor performance and excessive spending, suggesting that a sale could value Pacira at $2.7 billion, or $66 per share. This potential valuation is approximately three times the current share price and represents about 15 times the projected 2027 earnings.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.